MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial.

Conclusions: Our study validates the role of microRNA-31-3p as potential predictive biomarker of selection for anti-EGF mABs.
PMID: 30952636 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 4, 2019 Category: Cancer & Oncology Authors: Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Darvish Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki E, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, Bryan Tags: Clin Cancer Res Source Type: research